Investing.com -- The lawsuit filed by the U.S. Federal Trade Commission (FTC) against pharmacy benefit managers (PBMs) over insulin pricing practices is set to resume. The case had been temporarily ...

The FTC's general counsel had stayed the administrative complaint because the two FTC commissioners—Chair Andrew Ferguson and ...

UnitedHealth (UNH) and Cigna (CI) are under pressure as the FTC looks to resume a lawsuit against their PBMs. Read more here.

The U.S. Federal Trade Commission's lawsuit against pharmacy benefit managers (PBMs) over insulin pricing practices will ...

Federal Trade Commission Chair Andrew Ferguson has reversed course on his decision to recuse himself from the agency's legal ...

The health sector is experiencing significant disruptions, with the FTC halting a lawsuit against pharmacy-benefit managers ...

The FTC chair had previously been recused from the lawsuit. But after consulting with ethics lawyers, Ferguson changed his ...

FTC Chair Andrew Ferguson is no longer recusing himself from the matter, he said two days after a leadership shakeup at the ...

This brief covers significant developments in health, including FTC's hold on an insulin lawsuit, Hungary's outbreak control ...

The Federal Trade Commission late Tuesday stayed a lawsuit accusing pharmacy middlemen of gaming the system to inflate the ...

The Federal Trade Commission has temporarily halted its antitrust case against several top pharmacy benefit managers including Caremark Rx, Express Scripts and Optum Rx, due to a lack of participating ...

A Federal Trade Commission case against insulin price gouging has come to a screeching halt after two Democratic commissioners were fired by President Donald Trump.